Table 1. Duloxetine responders.
| hsa-miRNA | FC (T0 versus T8) | Adjusted P value |
|---|---|---|
| miR-425-3p | 0.46 | 2.639E−08 |
| miR-24-3p | 0.70 | 6.813E−06 |
| miR-503-5p | 0.45 | 6.987E−06 |
| miR-146a-5p | 0.60 | 3.748E−05 |
| miR-215-5p | 1.50 | 8.744E−05 |
| miR-3074-5p | 0.76 | 1.616E−04 |
| miR-1180-3p | 0.75 | 2.487E−04 |
| miR-425-5p | 0.86 | 0.001 |
| miR-324-5p | 0.78 | 0.001 |
| miR-146b-5p | 0.66 | 0.001 |
| miR-6750-3p | 1.27 | 0.005 |
| miR-6511a-3p | 1.21 | 0.007 |
| miR-361-5p | 0.84 | 0.009 |
| miR-3173-5p | 1.30 | 0.023 |
| miR-2110 | 0.81 | 0.026 |
| miR-3605-3p | 1.17 | 0.032 |
| miR-6881-3p | 1.27 | 0.032 |
| miR-30e-5p | 1.19 | 0.035 |
| miR-423-3p | 1.12 | 0.035 |
| miR-361-3p | 1.10 | 0.040 |
| miR-3184-5p | 1.12 | 0.050 |
| hsa-miR-636 | 1.14 | 0.050 |
FC, fold change; hsa, Homo sapiens.
Fold change is reported in the centre column and miRNAs are ranked according to adjusted P values (Benjamini–Hochberg correction for multiple testing).